The effects of ranibizumab (Lucentis<sup>®</sup>) on retinal function in isolated perfused vertebrate retina - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Ophthalmology Année : 2009

The effects of ranibizumab (Lucentis®) on retinal function in isolated perfused vertebrate retina

Résumé

Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). VEGF is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction.
Fichier principal
Vignette du fichier
PEER_stage2_10.1136%2Fbjo.2009.157511.pdf (142.92 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-00477847 , version 1 (30-04-2010)

Identifiants

Citer

Matthias Lüke, Kai Januschowski, Julia Lüke, Swaantje Peters, Nick Wirtz, et al.. The effects of ranibizumab (Lucentis®) on retinal function in isolated perfused vertebrate retina. British Journal of Ophthalmology, 2009, 93 (10), pp.1396-n/a. ⟨10.1136/bjo.2009.157511⟩. ⟨hal-00477847⟩

Collections

PEER
52 Consultations
375 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More